Johan Wallin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Johan Wallin has a total of 57 co-authors. Here are the top co-authors by number of shared publications:
- Andres McAllister
BioInvent International AB, Lund, Sweden
15 shared publications - Björn Frendéus
BioInvent International AB, Lund, Sweden
15 shared publications - Danijela Lindahl
BioInvent International AB, Lund, Sweden
15 shared publications - Ingrid Karlsson
BioInvent International AB, Lund, Sweden
15 shared publications - Ingrid Teige
BioInvent International AB, Lund, Sweden
15 shared publications - Linda Mårtensson
BioInvent International AB, Lund, Sweden
15 shared publications
Latest Publications
- Open Access
- 11 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF20
Anti-TNFR2 Antibody BI-1808 Induces Tumor Regression and Antitumor T-cell Immunity through Treg and Myeloid Cell Modulation in Patients with Solid Tumors
Purpose: The aim of the study is to clinically evaluate the safety, pharmacodynamic (PD) biomarkers, and efficacy of BI-1808, a first-in-class ligand-blocking, Fcγ receptor (FcγR)–engaging anti-TNFR2 antibody, as a novel immunotherapy approach to enhance antitumor immunity in patients with solid cancer. Patients and Methods: Preclinical modeling in syngeneic tumor models was used to assess the relationship between dose, pharmacokinetics (PK), receptor occupancy (RO), and efficacy, as well as PD biomarkers measured in peripheral blood and tumors. These findings informed dosing and analyses in a first-in-human phase I dose-escalation trial in patients with solid cancers. Results: BI-1808 was safe and well tolerated, showed expected PK, and achieved full RO throughout the 3-week dosing interval. Tumor regression was observed in two patients, one with non–small cell lung cancer and one with gastrointestinal sarcoma. Stable disease was observed in 6 of 21 evaluable patients. Tumor regression was preceded by increases in circulating CX3CR1+CD8+ T cells and tumor-infiltrating CD8+ T cells, consistent with the activation of antitumor immunity. PD analyses were consistent with the preclinically characterized mechanism of action, including dose-dependent reduction of regulatory T cells, monocyte activation, and serum cytokines indicating myeloid reprogramming, tertiary lymphoid structure formation, and CD8+ T-cell activation. Conclusions: These early clinical findings support further development of ligand-blocking, FcγR-engaging anti-TNFR2 antibodies as a safe and mechanistically distinct cancer immunotherapy strategy. The excellent safety profile of BI-1808 makes it well-suited for combination with other immunotherapies, targeted agents, chemotherapeutics, cell therapies, and antibody–drug conjugates.
- 11 November 2026
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- p. OF1-OF20
Open AccessAnti-TNFR2 Antibody BI-1808 Induces Tumor Regression and Antitumor T-cell Immunity through Treg and Myeloid Cell Modulation in Patients with Solid Tumors
Purpose: The aim of the study is to clinically evaluate the safety, pharmacodynamic (PD) biomarkers, and efficacy of BI-1808, a first-in-class ligand-blocking, Fcγ receptor (FcγR)–engaging anti-TNFR2 antibody, as a novel immunotherapy approach to enhance antitumor immunity in patients with solid cancer. Patients and Methods: Preclinical modeling in syngeneic tumor models was used to assess the relationship between dose, pharmacokinetics (PK), receptor occupancy (RO), and efficacy, as well as PD biomarkers measured in peripheral blood and tumors. These findings informed dosing and analyses in a first-in-human phase I dose-escalation trial in patients with solid cancers. Results: BI-1808 was safe and well tolerated, showed expected PK, and achieved full RO throughout the 3-week dosing interval. Tumor regression was observed in two patients, one with non–small cell lung cancer and one with gastrointestinal sarcoma. Stable disease was observed in 6 of 21 evaluable patients. Tumor regression was preceded by increases in circulating CX3CR1+CD8+ T cells and tumor-infiltrating CD8+ T cells, consistent with the activation of antitumor immunity. PD analyses were consistent with the preclinically characterized mechanism of action, including dose-dependent reduction of regulatory T cells, monocyte activation, and serum cytokines indicating myeloid reprogramming, tertiary lymphoid structure formation, and CD8+ T-cell activation. Conclusions: These early clinical findings support further development of ligand-blocking, FcγR-engaging anti-TNFR2 antibodies as a safe and mechanistically distinct cancer immunotherapy strategy. The excellent safety profile of BI-1808 makes it well-suited for combination with other immunotherapies, targeted agents, chemotherapeutics, cell therapies, and antibody–drug conjugates.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Figure S2. Combined treatment of anti-HER2 and mBI-1607 results in an increased influx/expansion of monocytes, NK-cells and B-cells compared to single treatment with anti-HER2. Tumors were dissected out from TUBO bearing mice 8 days post treatment start. Single cell suspensions were analyzed by FACS. Each dot is one animal. ***= p<0,001 *=p<0,05 as calculated using one-way ANOVA.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Figure S2. Combined treatment of anti-HER2 and mBI-1607 results in an increased influx/expansion of monocytes, NK-cells and B-cells compared to single treatment with anti-HER2. Tumors were dissected out from TUBO bearing mice 8 days post treatment start. Single cell suspensions were analyzed by FACS. Each dot is one animal. ***= p<0,001 *=p<0,05 as calculated using one-way ANOVA.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Table S1: Treatment-Emergent Adverse Events (TEAE) by System Organ Class and Preferred Term for Phase 1
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Table S1: Treatment-Emergent Adverse Events (TEAE) by System Organ Class and Preferred Term for Phase 1
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Data from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Purpose:BI-1607 is a human mAb that specifically blocks FcγRIIB, the sole inhibitory Fc receptor and master regulator of humoral and innate immune homeostasis. These studies evaluated preclinical antitumor activity using a BI-1607 murine surrogate (mBI-1607) and the safety, tolerability, pharmacokinetics, and pharmacodynamics of the compound in combination with trastuzumab in patients with HER2-positive advanced solid tumors (NCT05555251).Patients and Methods:Immunocompetent syngeneic mouse breast tumor (TUBO) and melanoma (B16-F10) models were used to evaluate in vivo antitumor activity in combination (anti-HER2 and anti-gp75). Ascending doses of BI-1607 administered intravenously every 3 weeks in combination with trastuzumab were evaluated in 18 patients with HER2-positive cancer. The primary objective was to assess the safety and tolerability of BI-1607 by determining dose-limiting toxicities and the maximum tolerated dose or maximum administered dose and identifying a recommended phase 2 dose.Results:mBI-1607 enhanced tumor-targeting antibody efficacy and animal survival. BI-1607/trastuzumab was well tolerated, with dose-limiting toxicity (rash) in one patient (5.6%) at 900 mg; the maximum tolerated dose was not reached. Treatment-emergent adverse events grade ≥3 occurred in five patients (28%), including exanthema, increase in liver enzymes, urticaria, acute kidney injury, and aggravated condition. Overall best response was stable disease, observed in seven of the nine evaluable patients (78%). BI-1607 exhibits linear pharmacokinetics for doses above 500 mg, and full receptor saturation was observed throughout the 21 days at 700 mg. No antidrug antibodies were observed.Conclusions:The enhancing effect on tumor direct-targeting antibodies observed preclinically, together with the favorable safety profile in patients, supports further investigation of BI-1607.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Purpose:BI-1607 is a human mAb that specifically blocks FcγRIIB, the sole inhibitory Fc receptor and master regulator of humoral and innate immune homeostasis. These studies evaluated preclinical antitumor activity using a BI-1607 murine surrogate (mBI-1607) and the safety, tolerability, pharmacokinetics, and pharmacodynamics of the compound in combination with trastuzumab in patients with HER2-positive advanced solid tumors (NCT05555251).Patients and Methods:Immunocompetent syngeneic mouse breast tumor (TUBO) and melanoma (B16-F10) models were used to evaluate in vivo antitumor activity in combination (anti-HER2 and anti-gp75). Ascending doses of BI-1607 administered intravenously every 3 weeks in combination with trastuzumab were evaluated in 18 patients with HER2-positive cancer. The primary objective was to assess the safety and tolerability of BI-1607 by determining dose-limiting toxicities and the maximum tolerated dose or maximum administered dose and identifying a recommended phase 2 dose.Results:mBI-1607 enhanced tumor-targeting antibody efficacy and animal survival. BI-1607/trastuzumab was well tolerated, with dose-limiting toxicity (rash) in one patient (5.6%) at 900 mg; the maximum tolerated dose was not reached. Treatment-emergent adverse events grade ≥3 occurred in five patients (28%), including exanthema, increase in liver enzymes, urticaria, acute kidney injury, and aggravated condition. Overall best response was stable disease, observed in seven of the nine evaluable patients (78%). BI-1607 exhibits linear pharmacokinetics for doses above 500 mg, and full receptor saturation was observed throughout the 21 days at 700 mg. No antidrug antibodies were observed.Conclusions:The enhancing effect on tumor direct-targeting antibodies observed preclinically, together with the favorable safety profile in patients, supports further investigation of BI-1607.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Figure S6: Cytokine release with plate bound antibodies. 1x105 PBMCs resuspended in fresh cell culture media containing fetal bovine serum were stimulated with plate bound antibody for 48 hours at 37°C in 5% CO2. The cytokine levels in the culture supernatant were measured using a 7-plex customized MSD plate. A paired one-way ANOVA with Tukey’s multiple comparison was used to determine significance; * = p<0.05; ns = not significant. Lines indicate mean values for each cytokine; each dot is indicative of an individual healthy donor (n=6).
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Figure S6: Cytokine release with plate bound antibodies. 1x105 PBMCs resuspended in fresh cell culture media containing fetal bovine serum were stimulated with plate bound antibody for 48 hours at 37°C in 5% CO2. The cytokine levels in the culture supernatant were measured using a 7-plex customized MSD plate. A paired one-way ANOVA with Tukey’s multiple comparison was used to determine significance; * = p<0.05; ns = not significant. Lines indicate mean values for each cytokine; each dot is indicative of an individual healthy donor (n=6).
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Figure S8: Cytokines measured pre and post IV BI-1607 infusion. Dotted line represents upper limit normal range (according to manufactures instructions based on 27 individuals (MesoScale Discovery #K15049) or based on 10 healthy donors tested in-house with MesoScale Discovery kit #K15049).
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Figure S8: Cytokines measured pre and post IV BI-1607 infusion. Dotted line represents upper limit normal range (according to manufactures instructions based on 27 individuals (MesoScale Discovery #K15049) or based on 10 healthy donors tested in-house with MesoScale Discovery kit #K15049).
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Figure S7: Cytokine release in whole blood. Whole blood was stimulated with 5 μg/mL antibody added in solution to the cells for 48 hours at 37°C in 5% CO2. The cytokine levels in the culture supernatant were measured using a 7-plex customized MSD plate. A paired one-way ANOVA with Tukey’s multiple comparison was used to determine significance; ns = not significant. Lines indicate mean values for each cytokine; each dot is indicative of an individual healthy donor (n=6).
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Figure S7: Cytokine release in whole blood. Whole blood was stimulated with 5 μg/mL antibody added in solution to the cells for 48 hours at 37°C in 5% CO2. The cytokine levels in the culture supernatant were measured using a 7-plex customized MSD plate. A paired one-way ANOVA with Tukey’s multiple comparison was used to determine significance; ns = not significant. Lines indicate mean values for each cytokine; each dot is indicative of an individual healthy donor (n=6).
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Figure S3: Individual B-cells (%) over time stratified by dose cohort level and subject. Only subjects with more than one B-cell measurement are displayed. The red area marks normal B-cell ranges.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Figure S3: Individual B-cells (%) over time stratified by dose cohort level and subject. Only subjects with more than one B-cell measurement are displayed. The red area marks normal B-cell ranges.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Figure S1. Individual tumor growth curves in the subcutaneous TUBO breast cancer model (n=12). Anti-HER2 in combination with mBI-1607 demonstrates delayed tumor growth and an increased number of complete responders (CR) compared to anti-HER2 treatment alone.
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Figure S1. Individual tumor growth curves in the subcutaneous TUBO breast cancer model (n=12). Anti-HER2 in combination with mBI-1607 demonstrates delayed tumor growth and an increased number of complete responders (CR) compared to anti-HER2 treatment alone.
- Open Access
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Representativeness of Study Participants
- 1 December 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors
Representativeness of Study Participants